Zimmer Biomet Holdings, Inc. reports developments across its global medical technology business, including orthopedic reconstructive implants, surgical products, and integrated digital and robotic technologies that use data, analytics and artificial intelligence. Company updates commonly cover quarterly results and guidance, dividend actions, health care conference appearances, executive leadership changes, and clinical or operational data presented at orthopedic meetings.
Product-focused announcements describe musculoskeletal care technologies such as Oxford Cementless Partial Knee, Persona OsseoTi Keel Tibia, and HAMMR Automated Hip Impaction System, alongside broader portfolio themes in knees, hips, smart implants, robotics, AI and medical education.
Zimmer Biomet (NYSE: ZBH) announced it now expects to repurchase up to $1 billion of common stock in fiscal 2026, a $250 million increase from its prior assumption.
All buybacks will occur under the existing $1.5 billion authorization approved in February 2026.
Zimmer Biomet (NYSE: ZBH) announced management will participate in the Bank of America Securities Health Care Conference on Wednesday, May 13, 2026, with a fireside chat at 8:40 a.m. PT (11:40 a.m. ET). A live audio webcast will be available on the company Investor Relations website and for replay after the session.
Zimmer Biomet (NYSE: ZBH) reported Q1 2026 net sales of $2.087 billion, up 9.3% reported, 6.8% constant currency and 2.9% organic constant currency. GAAP net earnings were $238.1 million and adjusted net earnings $409.4 million. Diluted EPS was $1.22 and adjusted diluted EPS $2.09. The company generated $359.4 million operating cash flow and $245.9 million free cash flow, repurchased $250 million of shares, and raised 2026 adjusted EPS and FCF expectations.
Zimmer Biomet (NYSE: ZBH) announced that Suketu Upadhyay, Chief Financial Officer and Executive Vice President, Finance, Operations and Supply Chain, will depart effective April 28, 2026, to pursue a new professional opportunity. The company named Paul Stellato, Controller and Chief Accounting Officer, as interim CFO while it conducts an internal and external search for a permanent successor.
Stellato joined Zimmer Biomet in May 2022, has more than 20 years of finance and investor-relations experience, and previously held senior finance roles at Xylem and ITT; he is a CPA with degrees from Villanova and NYU Stern.
Zimmer Biomet (NYSE: ZBH) will webcast its first quarter 2026 earnings conference call on Tuesday, April 28, 2026 at 8:30 a.m. ET. A quarterly results news release will be posted that day at 6:30 a.m. ET. The live audio webcast and replay will be available via the company's Investor Relations website, and U.S./Canada dial-in and international telephone numbers with conference ID are provided for live participation.
Zimmer Biomet (NYSE: ZBH) appointed Jonathan M. Vigdorchik, M.D., as Chief Science, Technology and Medical Affairs Officer, effective April 14, 2026. He will report to Ivan Tornos and oversee the company's global technology portfolio, including AI, robotics, smart implants and data, plus Medical Education and the Global Advisory Board.
Dr. Vigdorchik joins from Hospital for Special Surgery, previously served as Zimmer Biomet Chief Medical Technology Advisor for Adult Reconstruction and Hip Implants, and holds academic roles including Associate Professor at Weill Cornell.
Zimmer Biomet (NYSE: ZBH) will present new clinical and operational data and showcase robotic, digital and implant innovations at the AAOS 2026 Annual Meeting on March 5-9, 2026. The company will feature products including ROSA Knee with OptimiZe, Persona IQ, Monogram TKA, Oxford Cementless Partial Knee and Z1 Femoral Hip.
Arnold Schwarzenegger will appear as the conference Presidential Guest Speaker on March 5 at 10:30 a.m. CT alongside CEO Ivan Tornos and AAOS President Ned Amendola; multiple poster and data presentations will address safety, gait metrics, readmissions and ASC efficiency.
Zimmer Biomet (NYSE: ZBH) announced a quarterly cash dividend of $0.24 per share for Q1 2026. The dividend is payable on or about April 30, 2026 to shareholders of record at the close of business on March 31, 2026.
Zimmer Biomet (NYSE: ZBH) reported Q4 2025 net sales of $2.244B (up 10.9% reported; 5.4% organic constant currency) and full-year sales of $8.232B (up 7.2% reported; 3.9% organic). GAAP diluted EPS were $0.70 Q4 and $3.55 FY; adjusted EPS were $2.42 Q4 and $8.20 FY. The company generated $1.697B operating cash flow and $1.172B free cash flow, closed three acquisitions, and announced a new $1.5B share repurchase authorization commencing Feb 9, 2026. Full-year 2026 guidance targets ~2.5%–4.5% reported revenue growth and adjusted EPS of $8.30–$8.45.
Zimmer Biomet (NYSE: ZBH) announced its fourth-quarter 2025 earnings conference call will be webcast on Tuesday, February 10, 2026 at 8:30 a.m. ET. A news release with quarterly results will be published the same day at 6:30 a.m. ET. A live audio webcast and replay will be available via the company's investor relations site: https://investor.zimmerbiomet.com. U.S. and Canada dial-in is (800) 330-6710; international callers may use +1 (213) 279-1505. Use conference ID 7090861 to join the call.